New Strong Sell Stocks for January 28th
AGL, ASHTY and CCOZY have been added to the Zacks Rank #5 (Strong Sell) List on January 28, 2024.
New Strong Sell Stocks for January 24th
WMS, AGL and EADSY have been added to the Zacks Rank #5 (Strong Sell) List on January 24, 2025.
New Strong Sell Stocks for January 21st
VLVLY, AGL and APOG have been added to the Zacks Rank #5 (Strong Sell) List on January 21, 2025.
New Strong Sell Stocks for December 31st
AGL, AMPH and CR have been added to the Zacks Rank #24 (Strong Sell) List on December 31, 2024.
New Strong Sell Stocks for December 13th
AGL, BKGFY and BERY have been added to the Zacks Rank #5 (Strong Sell) List on December 13, 2024.
New Strong Sell Stocks for December 4th
ATI, ARLP and AGL have been added to the Zacks Rank #5 (Strong Sell) List on December 4, 2024.
New Strong Sell Stocks for December 2nd
ATI, ATS and AGL have been added to the Zacks Rank #5 (Strong Sell) List on December 2, 2024.
Agilon Health price target lowered to $2 from $5 at Barclays
Barclays lowered the firm's price target on Agilon Health to $2 from $5 and keeps an Underweight rating on the shares. The company's Q3 results underscore the lack of visibility into real-time trends and limited ability to take control of negative developments, the analyst tells investors in a research note.
agilon health, inc. (AGL) Q3 2024 Earnings Call Transcript
agilon health, inc. (NYSE:AGL ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Leland Thomas - Senior Manager-Investor Relations Steven Sell - Chief Executive Officer Jeffrey Schwaneke - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Justin Lake - Wolfe Research Adam Ron - Bank of America George Hill - Deutsche Bank Sameer Patel - Evercore Ryan Langston - TD Cowen Stephen Baxter - Wells Fargo Andrew Mok - Barclays Jack Slevin - Jefferies Michael Ha - Baird Thomas Keller - RBC Daniel Grosslight - Citi Operator Good afternoon and thank you for joining the agilon health Third Quarter 2024 Earnings Conference Call.
agilon health Plunges On A Poor Prognosis (Rating Downgrade)
I initially rated agilon health, inc. as a “hold” due to its volatile financial results and uncertain future, but recent developments necessitate a downgrade to 'sell'. The company's stock plummeted 60.1% since my last article, driven by disappointing Q3 results and reduced guidance, despite revenue growth. Rising medical costs and expansion expenses have severely impacted profitability, with a significant increase in net loss and negative EBITDA.
Here's What Key Metrics Tell Us About Agilon (AGL) Q3 Earnings
Although the revenue and EPS for Agilon (AGL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Agilon Health (AGL) Reports Q3 Loss, Lags Revenue Estimates
Agilon Health (AGL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.06 per share a year ago.
